Prevention and treatment of melanoma by TSA-treated (irradiated) tumor cell vaccine

<p><b>Copyright information:</b></p><p>Taken from "An epigenetic vaccine model active in the prevention and treatment of melanoma"</p><p>http://www.translational-medicine.com/content/5/1/64</p><p>Journal of Translational Medicine 2007;5():64-64.</p><p>Published online 10 Dec 2007</p><p>PMCID:PMC2231344.</p><p></p> ) Vaccination with TSA-treated (500 nM for 48 h) and irradiated (2000 Gy) B16 cells prevents B16 tumor generation. Three weeks after s.c. inoculation of TSA-treated [TSA-radiation] or untreated [radiation] B16 (1 × 10) cells in B6 mice (16 in each group); all tumor-free mice were challenged s.c. with wild type B16 (1 × 10) cells and observed for 40 days. Percentage of tumor-free mice is presented in the Kaplan-Meier plot. ) Suppression of primary tumor growth by TSA-treated and irradiated melanoma vaccine. Groups of B6 mice bearing palpable B16 (5 days tumor growth) were treated s.c. with TSA-treated and irradiated B16 [TSA-radiation] or untreated irradiated B16 (1 × 10cells) [radiation] in the opposite side of the trunk. A group of tumor-bearing mice did not receive any treatment [no treatment]. The number of tumor-free mice compared to total numbers used in each group is shown in parentheses at 42 days after treatment. ) Induction of long-term immunity in tumor-bearing mice treated with epigenetically altered melanoma vaccine. B16 tumor-bearing mice that became tumor-free following vaccine treatment were re-challenged s.c. with wild type B16 (1 × 10cells). Kaplan-Meier plot shows tumor-free survival of mice in both TSA-radiation and radiation groups after re-challenge